Gilead sub­mits an NDA for its big block­buster hope­ful

The head­lines for Gilead’s block­buster hope­ful fil­go­tinib have not al­ways been kind.

In ad­di­tion to the wider safe­ty con­cerns with JAK in­hibitors, Gilead’s ver­sion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER